GlassScriptPhysician profile
Caitlin Lutz
NPI 1457724585
$9,911.74
in general payments reported to CMS, 2019-2025
24 companies · $1,683 in 2025
The $1,683 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,365 · 2022: $2,903 · 2023: $993 · 2024: $1,967 · 2025: $1,683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,266 · Education: $377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,266.44 |
| Education | $377.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,732.20 | 2021-2025 | |
| Janssen Biotech, INC. | $1,396.92 | 2021-2025 | Tremfya, Simponi, Stelara |
| Regeneron Healthcare Solutions, INC. | $675.13 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $650.48 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $485.29 | 2021-2025 | Ilumya |
| Dermavant Sciences, INC. | $466.83 | 2023-2024 | Vtama |
| Incyte Corporation | $460.07 | 2021-2025 | Opzelura |
| Genzyme Corporation | $446.86 | 2021-2025 | |
| Pfizer INC. | $391.15 | 2021-2025 | |
| Organon LLC | $324.57 | 2025 | Vtama |
| Lilly USA, LLC | $324.49 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $255.31 | 2023-2025 | Sotyktu |
| Leo Pharma INC. | $220.93 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $182.40 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $180.59 | 2021-2024 | Cabtreo, Arazlo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $167.75 | 2022-2023 | |
| Galderma Laboratories, L.P. | $138.39 | 2022-2025 | Nemluvio, Twyneo, Epsolay |
| Janssen Scientific Affairs, LLC | $124.52 | 2021 | |
| Epi Health, LLC | $86.49 | 2021-2022 | |
| Ucb, INC. | $57.65 | 2021-2025 | Bimzelx |
| Amgen INC. | $53.70 | 2021-2024 | Otezla |
| Almirall LLC | $41.86 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.82 | 2023-2024 | Cyltezo |
| Dermira, INC. | $16.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Lutz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.